ArticleAntimicrobial agents and chemotherapy2012
Prevalence and molecular characterization of extended-spectrum-β-lactamase-producing Enterobacteriaceae in a pediatric patient population.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Prevalence of extended-spectrum-β-lactamase-producingAntimicrobial resistance and infection control · 2018Pooled it
- Prevalence and characterization of bacterial rectal colonization patterns in pediatric patients: A cross-sectional study.New microbes and new infections · 2026Article
- First report of carbapenems encoding multidrug-resistant gram-negative bacteria from a pediatric hospital in Gaza Strip, Palestine.BMC microbiology · 2024Article
- Prevalence and molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolates from dairy cattle with endometritis in Gansu Province, China.BMC veterinary research · 2024Article
- Genome profiling of uropathogenic E. coli from strictly defined community-acquired UTI in paediatric patients: a multicentric study.Antimicrobial resistance and infection control · 2023Article
- Prevalence of extended spectrum beta lactamase and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Gram negative bacilli isolates from pediatric patient population in Gaza strip.BMC infectious diseases · 2023Article
- EVALUATION OF PHENOTYPIC AND MOLECULAR TECHNIQUE IN THE DETECTION OF EXTENDED SPECTRUM BETA-LACTAMASE (ESBL)-PRODUCING GRAM NEGATIVE BACILLI IN OGUN STATE, NIGERIA.Annals of Ibadan postgraduate medicine · 2022Article
- Antimicrobial Resistance Profiling and Molecular Epidemiological Analysis of Extended Spectrum β-Lactamases Produced by Extraintestinal InvasiveFrontiers in microbiology · 2021Article
- High Prevalence of CTX-M Type Extended-Spectrum Beta-Lactamase Genes and Detection of NDM-1 Carbapenemase Gene in Extraintestinal PathogenicPathogens (Basel, Switzerland) · 2020Article
- Prevalence of Extended-Spectrum Beta-Lactamase-ProducingInfection and drug resistance · 2020Article
- Article
- Genomic Surveillance of Ceftriaxone-ResistantFrontiers in microbiology · 2020Article
- The Phylogenetic Relatedness ofInfection and drug resistance · 2020Article
- Molecular characterization of invasive Enterobacteriaceae from pediatric patients in Central and Northwestern Nigeria.PloS one · 2020Article
- Molecular Characterization of Extended-Spectrum β-LactamaseThe American journal of tropical medicine and hygiene · 2019Article
- Extended-SpectrumBioMed research international · 2019Article
- Incidence and Outcomes of Infections Caused by Multidrug-Resistant Enterobacteriaceae in Children, 2007-2015.Journal of the Pediatric Infectious Diseases Society · 2018Article
- Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population.Antimicrobial resistance and infection control · 2018Article
- An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate.Journal of clinical microbiology · 2018Article
- Risk Factors for Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Carriage Upon Pediatric Intensive Care Unit Admission.Infection control and hospital epidemiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Very little is known about the prevalence and composition of various types of extended-spectrum β-lactamases (ESBL) in pediatric patients. The aims of this study were the following: (i) to determine the prevalence of ESBLs among Enterobacteriaceae in a tertiary-care pediatric population; (ii) to characterize the genetic composition of the identified ESBL enzymes; and (iii) to determine the relative prevalence of CTX-M enzymes and Escherichia coli ST131 strains among ESBL-producing isolates in the same pediatric patient population. Among the 1,430 Enterobacteriaceae isolates screened for elevated MICs to cefotaxime and/or ceftazidime from pediatric patients during a 1-year period, 94 isolates possessed at least one ESBL gene. CTX-M was the most commonly isolated ESBL type, consisting of 74% of all ESBLs versus 27% TEM and 24% SHV enzymes. Sequence analysis and probe-specific real-time PCR revealed that the majority (80%) of the CTX-M-type ESBLs were CTX-M-15 enzymes, followed by CTX-M-14 (17%) and CTX-M-27(2.8%). Multilocus sequence typing (MLST) and repetitive PCR analyses revealed that the relative prevalence of ST131 among ESBL-producing E. coli isolates is 10.2%. This study highlights the growing problem of ESBL resistance in pediatric Enterobacteriaceae isolates and demonstrates a transition toward the predominance of CTX-M-type enzymes among ESBL-producing Enterobacteriaceae organisms causing pediatric infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.